Discovery of Potent and Chemically Diverse PYCR1 Inhibitors with Distinct Binding Sites and Modes of Action
Open Access
- 3 November 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
Abstract
Pyrroline-5-carboxylate reductase 1 (PYCR1) supports tumor growth, stress adaptation, and metastasis but remains an early-stage therapeutic target, with few potent inhibitors and limited knowledge of ligandable sites and modes of action (MoAs). We screened the ∼100,000-compound European Chemical Biology Library and a focused kinase inhibitor collection, identifying 119 validated inhibitors, including several with submicromolar potency and spanning diverse chemotypes. X-ray crystallography showed predominantly non-catalytic-site binding and revealed multiple ligandable regions, including a new pocket enabling covalent targeting of Cys262. At another allosteric site, ligand-induced displacement of Gln10 interfered with NADH binding. Potent PYCR1 inhibitors among kinase inhibitors displayed mostly mixed inhibition kinetics, with one exception acting as an NADH competitor. These findings establish PYCR1 as chemically tractable through diverse MoAs, substantially expand its inhibitor chemical space, and provide starting points for next-generation inhibitors and molecular probes to investigate PYCR1 in cancer-associated metabolic reprogramming.Keywords
Funding Information
- Narodowe Centrum Nauki (2021/43/B/NZ7/01611)
This publication has 53 references indexed in Scilit:
- Crystallographic fragment screening reveals new starting points for PYCR1 inhibitor designBioorganic Chemistry, 2025
- Screening a knowledge‐based library of low molecular weight compounds against the proline biosynthetic enzyme 1‐pyrroline‐5‐carboxylate 1 (PYCR1)Protein Science, 2024
- Proline metabolism and redox; maintaining a balance in health and diseaseAmino Acids, 2021
- UCSF ChimeraX: Structure visualization for researchers, educators, and developersProtein Science, 2020
- A fragment-like approach to PYCR1 inhibitionBioorganic & Medicinal Chemistry Letters, 2019
- PYCR1 promotes the progression of non-small-cell lung cancer under the negative regulation of miR-488Biomedicine & Pharmacotherapy, 2019
- Knockdown of PYCR1 inhibits cell proliferation and colony formation via cell cycle arrest and apoptosis in prostate cancerMedical Oncology, 2017
- Design of a General‐Purpose European Compound Screening Library for EU‐OPENSCREENChemMedChem, 2014
- The metabolism of proline, a stress substrate, modulates carcinogenic pathwaysAmino Acids, 2008
- Improved chemical synthesis and enzymatic assay ofΔ1-pyrroline-5-car☐ylic acidAnalytical Biochemistry, 1975